Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 4
2006 1
2007 1
2009 3
2010 6
2011 3
2013 5
2014 6
2015 4
2016 6
2017 3
2018 5
2019 4
2020 5
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Cancer drug related cardiotoxicity during breast cancer treatment.
Giordano G, Spagnuolo A, Olivieri N, Corbo C, Campagna A, Spagnoletti I, Pennacchio RM, Campidoglio S, Pancione M, Palladino L, Villari B, Febbraro A. Giordano G, et al. Among authors: febbraro a. Expert Opin Drug Saf. 2016 Aug;15(8):1063-74. doi: 10.1080/14740338.2016.1182493. Epub 2016 Jul 6. Expert Opin Drug Saf. 2016. PMID: 27120499 Review.
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients.
Trevisan B, Pepe FF, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V, Cazzaniga ME; VICTOR Study Group. Trevisan B, et al. Among authors: febbraro a. Sci Rep. 2023 Jul 28;13(1):12255. doi: 10.1038/s41598-023-39386-x. Sci Rep. 2023. PMID: 37507480 Free PMC article.
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.
Cardone C, De Stefano A, Rosati G, Cassata A, Silvestro L, Borrelli M, Di Gennaro E, Romano C, Nappi A, Zanaletti N, Foschini F, Casaretti R, Tatangelo F, Lastoria S, Raddi M, Bilancia D, Granata V, Setola S, Petrillo A, Vitagliano C, Gargiulo P, Arenare L, Febbraro A, Martinelli E, Ciardiello F, Delrio P, Budillon A, Piccirillo MC, Avallone A. Cardone C, et al. Among authors: febbraro a. ESMO Open. 2023 Feb;8(1):100748. doi: 10.1016/j.esmoop.2022.100748. Epub 2023 Jan 3. ESMO Open. 2023. PMID: 36603521 Free PMC article. Clinical Trial.
A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
Ciccarese M, Orlando L, Fedele P, Schiavone P, Maiello E, Cilenti G, Aieta M, Bozza G, Forcignanò R, Febbraro A, Bordonaro R, Romito S, Rinaldi A, Borsellino N, Riccardi F, Pisconti S, Lorusso V, Colucci G, Surico G, Saracino V, Cinieri S; GOIM (Gruppo Oncologico dell’Italia Meridionale). Ciccarese M, et al. Among authors: febbraro a. Breast J. 2020 Sep;26(9):1857-1859. doi: 10.1111/tbj.13856. Epub 2020 May 20. Breast J. 2020. PMID: 32436244 Clinical Trial. No abstract available.
Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting.
Prete SD, Montella L, Arpino G, Buono G, Buonerba C, Dolce P, Fiorentino O, Aliberti M, Febbraro A, Savastano C, Colantuoni G, Riccardi F, Ruggiero A, Placido S, Orditura M. Prete SD, et al. Among authors: febbraro a. Oncotarget. 2020 Jun 2;11(22):2083-2091. doi: 10.18632/oncotarget.27603. eCollection 2020 Jun 2. Oncotarget. 2020. PMID: 32547706 Free PMC article.
Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer.
Cardone C, Martinelli E, Troiani T, Sforza V, Avallone A, Nappi A, Montesarchio V, Andreozzi F, Biglietto M, Calabrese F, Bordonaro R, Cordio S, Bregni G, Febbraro A, Garcia-Carbonero R, Feliu J, Cervantes A, Ciardiello F. Cardone C, et al. Among authors: febbraro a. ESMO Open. 2019 Aug 16;4(4):e000519. doi: 10.1136/esmoopen-2019-000519. eCollection 2019. ESMO Open. 2019. PMID: 31555481 Free PMC article.
BAG3 is a novel serum biomarker for pancreatic adenocarcinomas.
Falco A, Rosati A, Festa M, Basile A, De Marco M, d'Avenia M, Pascale M, Dal Piaz F, Tavano F, Di Mola FF, di Sebastiano P, Berloco PB, Nudo F, Caraglia M, Febbraro A, Barcaroli D, Scarpa A, Pezzilli R, De Laurenzi V, Turco MC. Falco A, et al. Among authors: febbraro a. Am J Gastroenterol. 2013 Jul;108(7):1178-80. doi: 10.1038/ajg.2013.128. Am J Gastroenterol. 2013. PMID: 23821002 No abstract available.
56 results